Navigation Links
Breast cancer diagnostic delay depends more on race than insurance
Date:10/3/2010

MIAMI Race and ethnicity appeared to affect diagnostic delay more than insurance status for women with breast abnormalities, as revealed by data presented at the Third American Association for Cancer Research Conference on The Science of Cancer Health Disparities, being held Sept. 30-Oct. 3, 2010.

Heather J. Hoffman, Ph.D., assistant professor of epidemiology and biostatistics at George Washington University School of Public Health and Health Services, and colleagues at the George Washington Cancer Institute, conducted a retrospective cohort study of 983 women examined for breast cancer between 1998 to 2009 at six hospitals and clinics in Washington, D.C.

Findings revealed that non-Hispanic black and Hispanic women with government or private insurance waited more than twice as long for a definitive diagnosis than non-Hispanic white women with government or private insurance.

Diagnostic delay time, or the amount of time between when abnormalities were found until a diagnosis was reached, for uninsured black women was more than twice as long as that of black women with private insurance. Although having private insurance reduced time to diagnosis for black women, they still waited significantly longer for a diagnosis than white women with private insurance.

"We were surprised by the fact that non-Hispanic black and Hispanic women with health insurance experienced greater delays than non-Hispanic white women with health insurance," Hoffman said. "We thought having health insurance would even the field among all women. Insured women should have had the same rapid evaluation regardless of race and ethnicity."

Among those with private insurance, diagnostic delay time, or the number of days from abnormal screening to definitive diagnosis, was 15.9 days for white women, 27.1 days for black women and 51.4 days for Hispanic women. Diagnostic delay times among those with government insurance were 11.9 days for white women, 39.4 days for black women and 70.8 days for Hispanic women. Finally, among those without insurance, diagnostic delay times were reported as 44.5 days for white women, 59.7 days for black women and 66.5 days for Hispanic women.

"Non-Hispanic black and Hispanic women should be the focus of breast cancer screening outreach and follow-up since they experience greater delays in diagnosis than non-Hispanic white women, regardless of type of insurance," Hoffman said. "In particular, we need to investigate the barriers to rapid workup in insured non-Hispanic black and Hispanic women first and then investigate barriers in all uninsured women."

"Health care professionals must stress follow-up with all non-Hispanic black and Hispanic women with breast abnormalities to assure they are diagnosed as soon as possible," she added.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Decreased survival for Puerto Rican women with triple-negative breast cancer subtype
2. Racial differences in breast cancer treatment persist despite similar economics
3. Marshall University researchers awarded more than $1 million for breast cancer studies
4. Fat stem cells safe for breast reconstruction when cancer is dormant, says Pitt team
5. Alcohol consumption after breast cancer diagnosis may increase recurrence risk
6. High-fat diet during puberty linked to breast cancer risk later in life
7. Vitamin A increases the presence of the HIV virus in breast milk
8. LOreal Fellowship winner seeks to understand breast cancer
9. Protein made by breast cancer gene purified
10. New breast cancer committee to establish federal research agenda
11. 1,500 worldwide experts debate the latest advances in breast pathologies treatments in Valencia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
(Date:1/26/2017)...  Crossmatch, a leading provider of security and identity ... combatting fraud, waste and abuse in assistance operations around ... on Disaster Relief conference in Panama City ... and foreign assistance organizations throughout Latin America ... a largely unacknowledged problem in the foreign assistance and ...
Breaking Biology News(10 mins):
(Date:2/15/2017)...  Trianni, Inc. („TRIANNI") gab heute bekannt, man ... über die Verwendung der The Trianni Mouse unterschrieben, ... Entdeckung monoklonaler Antikörper. Die Trianni Plattform ... das Janssen den Zugang zu einer ... für die schelle Isolierung vollständig menschlicher Therapeutika optimiert ...
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
(Date:2/15/2017)... 15, 2017 Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, will host ... at 8:00 AM EST on Thursday, February 16, 2017 ... program, the recently announced closing of a $10.5 million ... To participate in the live call and take ...
(Date:2/15/2017)... ... 2017 , ... Diameter Health (Diameter) and Lantana ... in the hands of Lantana analysts. The high-performance platform of Diameter combined with ... entities – all those mining value from clinical data – to get the ...
Breaking Biology Technology: